Pune-based Gennova Biopharmaceuticals had submitted data to the drug regulator this month, amid an increase in the number of Covid-19 cases. Gennova, a subsidiary of Pune-based drugmaker Emcure, has developed an Omicron-specific vaccine GEMCOVAC-OM which has been assessed for its safety and immunogenicity when administered as a booster in participants who have received two doses of either Covishield or Covaxin, the two main Covid-19 vaccines used in the immunisation drive.
